Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor

John P. Cooke

doi:10.1016/j.lfs.2007.01.061

Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor

John P. Cooke

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Abstract

An endothelial nicotinic acetycholine receptor (nAChR) mediates endothelial proliferation, survival, migration and tube formation in vitro, and angiogenesis in vivo. Exogenous nicotine stimulates this angiogenic pathway. This action of nicotine may contribute to tumor angiogenesis and tumor growth; atherosclerotic plaque neovascularization and progression; and other tobacco-related diseases. The endothelial nAChR mediates an angiogenic pathway that is interdependent with growth factor mediated pathways, as shown by pharmacological and molecular studies. The characterization of this new angiogenic pathway may provide a new therapeutic avenue for disorders of insufficient or pathological angiogenesis.

Original language	English (US)
Pages (from-to)	2347-2351
Number of pages	5
Journal	Life sciences
Volume	80
Issue number	24-25
DOIs	https://doi.org/10.1016/j.lfs.2007.01.061
State	Published - May 30 2007

Keywords

Acetylcholine
Angiogenesis
Endothelium
Nicotine

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/j.lfs.2007.01.061

Cite this

@article{9600283c6962496b91dd060c0b2dc8d1,

title = "Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor",

abstract = "An endothelial nicotinic acetycholine receptor (nAChR) mediates endothelial proliferation, survival, migration and tube formation in vitro, and angiogenesis in vivo. Exogenous nicotine stimulates this angiogenic pathway. This action of nicotine may contribute to tumor angiogenesis and tumor growth; atherosclerotic plaque neovascularization and progression; and other tobacco-related diseases. The endothelial nAChR mediates an angiogenic pathway that is interdependent with growth factor mediated pathways, as shown by pharmacological and molecular studies. The characterization of this new angiogenic pathway may provide a new therapeutic avenue for disorders of insufficient or pathological angiogenesis.",

keywords = "Acetylcholine, Angiogenesis, Endothelium, Nicotine",

author = "Cooke, {John P.}",

note = "Funding Information: This study was supported by grants from the National Institutes of Health (RO1 HL63685; RO1 AT/HL00204; PO1 AI50153; P01 AG18784); from Philip Morris Incorporated; and the Tobacco Related Disease Research Program (7RT-0128). Stanford University owns patents on the use of nACh receptor agonists and antagonists for disorders of inadequate or pathological angiogenesis. Dr. Cooke is an inventor on these patents, and receives royalties from the licenses. Dr. Cooke is a co-founder of and has equity in Athenagen Inc., which has licensed this technology. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.",

year = "2007",

month = may,

day = "30",

doi = "10.1016/j.lfs.2007.01.061",

language = "English (US)",

volume = "80",

pages = "2347--2351",

journal = "Life sciences",

issn = "0024-3205",

publisher = "Elsevier",

number = "24-25",

}

TY - JOUR

T1 - Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor

AU - Cooke, John P.

N1 - Funding Information: This study was supported by grants from the National Institutes of Health (RO1 HL63685; RO1 AT/HL00204; PO1 AI50153; P01 AG18784); from Philip Morris Incorporated; and the Tobacco Related Disease Research Program (7RT-0128). Stanford University owns patents on the use of nACh receptor agonists and antagonists for disorders of inadequate or pathological angiogenesis. Dr. Cooke is an inventor on these patents, and receives royalties from the licenses. Dr. Cooke is a co-founder of and has equity in Athenagen Inc., which has licensed this technology. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.

PY - 2007/5/30

Y1 - 2007/5/30

N2 - An endothelial nicotinic acetycholine receptor (nAChR) mediates endothelial proliferation, survival, migration and tube formation in vitro, and angiogenesis in vivo. Exogenous nicotine stimulates this angiogenic pathway. This action of nicotine may contribute to tumor angiogenesis and tumor growth; atherosclerotic plaque neovascularization and progression; and other tobacco-related diseases. The endothelial nAChR mediates an angiogenic pathway that is interdependent with growth factor mediated pathways, as shown by pharmacological and molecular studies. The characterization of this new angiogenic pathway may provide a new therapeutic avenue for disorders of insufficient or pathological angiogenesis.

AB - An endothelial nicotinic acetycholine receptor (nAChR) mediates endothelial proliferation, survival, migration and tube formation in vitro, and angiogenesis in vivo. Exogenous nicotine stimulates this angiogenic pathway. This action of nicotine may contribute to tumor angiogenesis and tumor growth; atherosclerotic plaque neovascularization and progression; and other tobacco-related diseases. The endothelial nAChR mediates an angiogenic pathway that is interdependent with growth factor mediated pathways, as shown by pharmacological and molecular studies. The characterization of this new angiogenic pathway may provide a new therapeutic avenue for disorders of insufficient or pathological angiogenesis.

KW - Acetylcholine

KW - Angiogenesis

KW - Endothelium

KW - Nicotine

UR - http://www.scopus.com/inward/record.url?scp=34249307450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249307450&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2007.01.061

DO - 10.1016/j.lfs.2007.01.061

M3 - Article

C2 - 17383685

AN - SCOPUS:34249307450

SN - 0024-3205

VL - 80

SP - 2347

EP - 2351

JO - Life sciences

JF - Life sciences

IS - 24-25

ER -

Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this